Consensus-based recommendations for the management of juvenile systemic sclerosis
…, C Pilkington, N Toplak, A Van Royen… - …, 2021 - academic.oup.com
Juvenile systemic sclerosis (JSSc) is a rare disease of childhood and currently no international
consensus exists with regard to its assessment and treatment. This SHARE (Single Hub …
consensus exists with regard to its assessment and treatment. This SHARE (Single Hub …
European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis—the SHARE initiative
Objectives IgA vasculitis (IgAV, formerly known as Henoch–Schönlein purpura) is the most
common cause of systemic vasculitis in childhood. To date, there are no internationally …
common cause of systemic vasculitis in childhood. To date, there are no internationally …
Consensus-based recommendations for the management of juvenile localised scleroderma
…, R Russo, N Toplak, A Van Royen… - Annals of the …, 2019 - ard.bmj.com
In 2012, a European initiative called Single Hub and Access point for paediatric
Rheumatology in Europe (SHARE) was launched to optimise and disseminate diagnostic and …
Rheumatology in Europe (SHARE) was launched to optimise and disseminate diagnostic and …
European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides–the SHARE initiative
Objectives The European initiative Single Hub and Access point for paediatric Rheumatology
in Europe (SHARE) aimed to optimize care for children with rheumatic diseases. Systemic …
in Europe (SHARE) aimed to optimize care for children with rheumatic diseases. Systemic …
Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells
…, F Broere, A van Royen… - Blood, The Journal …, 2016 - ashpublications.org
Autologous hematopoietic stem cell transplantation (HSCT) is increasingly considered for
patients with severe autoimmune diseases whose prognosis is poor with standard treatments. …
patients with severe autoimmune diseases whose prognosis is poor with standard treatments. …
Autologous haemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis
N Wulffraat, A van Royen, M Bierings, J Vossen, W Kuis - The Lancet, 1999 - thelancet.com
Background Autologous haemopoietic stem-cell transplantation (AHSCT) had been
described as a possible treatment for severe autoimmune disease refractory to conventional …
described as a possible treatment for severe autoimmune disease refractory to conventional …
Inflammatory mediators in human epilepsy: a systematic review and meta-analysis
…, KPJ Braun, A van Royen-Kerkhof… - Neuroscience & …, 2016 - Elsevier
Background Accumulating evidence suggests a role for inflammation in the pathophysiology
of epilepsy. Methods We performed a systematic review and meta-analysis of studies that …
of epilepsy. Methods We performed a systematic review and meta-analysis of studies that …
[HTML][HTML] Consensus-based recommendations for the management of juvenile dermatomyositis
…, LJ McCann, A van Royen-Kerkhof - Annals of the …, 2017 - ard.bmj.com
Background In 2012, a European initiative called Single Hub and Access point for pediatric
Rheumatology in Europe (SHARE) was launched to optimise and disseminate diagnostic …
Rheumatology in Europe (SHARE) was launched to optimise and disseminate diagnostic …
[HTML][HTML] An autoinflammatory disease with deficiency of the interleukin-1–receptor antagonist
…, J Frenkel, A van Royen-Kerkhoff… - … England Journal of …, 2009 - Mass Medical Soc
Background Autoinflammatory diseases manifest inflammation without evidence of infection,
high-titer autoantibodies, or autoreactive T cells. We report a disorder caused by mutations …
high-titer autoantibodies, or autoreactive T cells. We report a disorder caused by mutations …
Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease
…, BK Barham, HL Leavis, A van Royen-Kerkof… - Nature …, 2016 - nature.com
Systemic autoinflammatory diseases are driven by abnormal activation of innate immunity 1
. Herein we describe a new disease caused by high-penetrance heterozygous germline …
. Herein we describe a new disease caused by high-penetrance heterozygous germline …